Skip to main content

Table 3 Multivariate Cox proportional hazards ratios and 95% confidence intervals for the association between EndoPredict, selected clinicopathological variables and metastasis-free survival

From: Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial

Variables HR (95% CIa) P-value
EP 1.126 (1.041 to 1.219) 0.0031
Number Positive Nodes   <0.0001b
  1 to 3 Reference value  
  4 to 10 1.420 (0.932 to 2.166) 0.1030
  >10 3.605 (2.102 to 6.185) <0.0001
Age 0.983 (0.966 to 1.001) 0.0628
Tumor size   0.6631b
  ≤1 cm Reference value  
  >1 to ≤2 cm 0.789 (0.343 to 1.816) 0.5774
  >2 to ≤5 cm 1.042 (0.466 to 2.331) 0.9196
  >5 cm 0.880 (0.301 to 2.577) 0.8159
Treatment arm   0.9331b
  FEC Reference value  
  FEC-P 1.016 (0.697 to 1.482)  
Grade   0.4650b
  G1 Reference value  
  G2 1.662 (0.830 to 3.329) 0.1519
  G3 1.589 (0.747 to 3.377) 0.2290
  Unknown 1.198 (0.470 to 3.052) 0.7051
ER (Allred score c ) 0.980 (0.903 to 1.063) 0.6207
PR (Allred score c ) 0.965 (0.902 to 1.032) 0.2947
Ki67 quantitative 1.001 (0.986 to 1.016) 0.8982
  1. aCI: Confidence interval; EP: EndoPredict; EPclin: Combined molecular and clinical score; ER: Estrogen receptor; HR: Hazard ratio; MFS: Metastasis-free survival; PR: Progesterone receptor. bP-value of the variable’s overall effect on MFS. cAllred et al. [18]. Multivariate analyses included 534 patients and 116 events.